2
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
CNS
1
Conditions
Glioma
6
Astrocytoma
4
Oligodendroglioma
2
Recurrence
1
Pathologic Processes
1
Neuroectodermal Tumors
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoma, Follicular
1
Healthy Adult Participants
1
Disease Attributes
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
9
Pemetrexed
6
pembrolizumab
5
fludarabine
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
ponatinib
4
atezolizumab
4
Rituximab
4
Dexamethasone
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
Sunitinib
3
Melphalan
3
Lutetium
3
Doxorubicin
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
pomalidomide
2
osimertinib
2
napabucasin
2
isatuximab
2
fludarabine phosphate
2
ficlatuzumab
2
entrectinib
2
entinostat
2
durvalumab
2
cobimetinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
vorasidenib
×
Clear all
NCT05592743
2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing